SMO and cancer: Cyclopamine (an antagonist of Smo) has been reported to block the transduction of Hh canonical signaling in a dose-dependent manner by inhibiting Smo, and it is a drug used clinically to treat Hh pathway-related diseases and cancers [59,60].